ZA201905790B - Anti-lag-3 antibodies and uses thereof - Google Patents

Anti-lag-3 antibodies and uses thereof

Info

Publication number
ZA201905790B
ZA201905790B ZA2019/05790A ZA201905790A ZA201905790B ZA 201905790 B ZA201905790 B ZA 201905790B ZA 2019/05790 A ZA2019/05790 A ZA 2019/05790A ZA 201905790 A ZA201905790 A ZA 201905790A ZA 201905790 B ZA201905790 B ZA 201905790B
Authority
ZA
South Africa
Prior art keywords
lag
antibodies
autoimmune
stimulating
inflammatory
Prior art date
Application number
ZA2019/05790A
Other languages
English (en)
Inventor
Lei Fang
Zhengyi Wang
Bingshi Guo
Jingwu Zang
Wenqing Jiang
Yongqiang Wang
Original Assignee
I Mab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2017/074365 external-priority patent/WO2018152687A1/en
Application filed by I Mab filed Critical I Mab
Publication of ZA201905790B publication Critical patent/ZA201905790B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
ZA2019/05790A 2017-02-22 2019-09-02 Anti-lag-3 antibodies and uses thereof ZA201905790B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2017/074365 WO2018152687A1 (en) 2017-02-22 2017-02-22 Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof
CN2017088570 2017-06-16
PCT/CN2018/076940 WO2018153340A1 (en) 2017-02-22 2018-02-22 Anti-lag-3 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
ZA201905790B true ZA201905790B (en) 2025-03-26

Family

ID=63253327

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/05790A ZA201905790B (en) 2017-02-22 2019-09-02 Anti-lag-3 antibodies and uses thereof

Country Status (12)

Country Link
US (2) US10577421B2 (enExample)
EP (1) EP3389702A4 (enExample)
JP (1) JP6929951B2 (enExample)
KR (2) KR102236259B1 (enExample)
CN (1) CN109475617B (enExample)
AU (1) AU2018226298B2 (enExample)
CA (1) CA3053989C (enExample)
IL (1) IL268734A (enExample)
NZ (1) NZ756678A (enExample)
SG (1) SG11201907561PA (enExample)
WO (1) WO2018153340A1 (enExample)
ZA (1) ZA201905790B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118027197A (zh) 2017-07-06 2024-05-14 美勒斯公司 调节由细胞表达的生物活性的抗体
CA3109999A1 (en) * 2018-08-21 2020-02-27 Abl Bio Inc. Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
CN110066334B (zh) * 2019-03-22 2020-03-10 南京医科大学 抗Galectin-3的全人源化单域抗体及应用
CN112010976B (zh) * 2019-05-29 2022-07-01 山东博安生物技术股份有限公司 抗lag3抗体及其用途
CN110320367A (zh) * 2019-05-30 2019-10-11 广州医科大学附属第一医院（广州呼吸中心） 基于lag-3的诊断试剂盒及其在帕金森病诊断产品上的应用
EP4268842A3 (en) * 2019-06-14 2024-05-22 ABL Bio, Inc. BISPECIFIC ANTIBODY AGAINST a-SYN/IGF1R AND USE THEREOF
CN112513097B (zh) * 2019-07-11 2021-10-29 武汉友芝友生物制药有限公司 四价对称双特异性抗体
CN114206940B (zh) * 2019-07-23 2023-09-22 南京金斯瑞生物科技有限公司 抗cd47/抗lag-3双特异抗体及其制备方法和应用
CN113004407B (zh) * 2019-12-20 2022-11-11 广东菲鹏制药股份有限公司 Lag3抗体及其应用
CN113348182B (zh) * 2019-12-30 2022-07-12 上海海路生物技术有限公司 Lag-3抗体及其医药用途
WO2021163989A1 (en) 2020-02-21 2021-08-26 Yinnuolai Biotech Ltd. Anti-baff receptor antibodies and uses thereof
CN116102644B (zh) * 2020-05-19 2025-06-03 益科思特(北京)医药科技发展有限公司 抗新型冠状病毒Spike蛋白抗体及其应用
CN114605544B (zh) * 2020-06-05 2023-08-01 北京天广实生物技术股份有限公司 Lag3抗体及其用途
CN112062832B (zh) * 2020-09-24 2021-08-03 河南赛诺特生物技术有限公司 Galectin-3抗原表位肽、抗原、抗体、杂交瘤细胞株及试剂盒
CN114621345B (zh) * 2020-12-10 2022-11-29 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
EP4288455A1 (en) 2021-02-03 2023-12-13 Mozart Therapeutics, Inc. Binding agents and methods of using the same
CN115490764B (zh) * 2021-06-18 2025-06-03 佛山热休生物技术有限公司 Lgals3的表位肽及所述表位肽与热休克蛋白的复合物
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023178201A2 (en) * 2022-03-15 2023-09-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of identifying anti-lag-3 agents
CN115819595B (zh) * 2023-01-03 2023-05-16 上海百英生物科技股份有限公司 一种抗lag3纳米抗体及其制备方法与应用
WO2024189628A1 (en) * 2023-03-16 2024-09-19 Technion Research And Development Foundation Limited Lag-3 inhibition for enhanced antiviral immune response
EP4685152A1 (en) * 2023-03-20 2026-01-28 Kyungpook National University Industry-Academic Cooperation Foundation Peptide binding to lag-3 and use thereof
TW202509063A (zh) * 2023-08-21 2025-03-01 瑞士商百濟神州瑞士有限責任公司 用抗lag3、抗pd-1和化學療法治療食管癌
WO2025128836A1 (en) * 2023-12-13 2025-06-19 Eli Lilly And Company Lag-3 agonist antibodies
WO2026059921A1 (en) 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bcma inhibitors in combination with lag3 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
US10344088B2 (en) * 2013-03-15 2019-07-09 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
EP3077504B1 (en) * 2013-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
KR102442436B1 (ko) * 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
MA41463A (fr) * 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
TWI773646B (zh) * 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
CN114853891A (zh) * 2015-07-22 2022-08-05 索伦托药业有限公司 与lag3结合的抗体治疗剂
HUE068868T2 (hu) * 2015-07-30 2025-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások

Also Published As

Publication number Publication date
US20200071403A1 (en) 2020-03-05
KR20180113195A (ko) 2018-10-15
JP2020508303A (ja) 2020-03-19
KR102144317B1 (ko) 2020-08-18
JP6929951B2 (ja) 2021-09-01
CA3053989C (en) 2024-10-29
EP3389702A4 (en) 2019-08-14
WO2018153340A1 (en) 2018-08-30
SG11201907561PA (en) 2019-09-27
CN109475617A (zh) 2019-03-15
AU2018226298A1 (en) 2019-09-19
IL268734A (en) 2019-10-31
CN109475617B (zh) 2022-05-17
EP3389702A1 (en) 2018-10-24
NZ756678A (en) 2023-02-24
US20190225687A1 (en) 2019-07-25
KR20190111894A (ko) 2019-10-02
KR102236259B1 (ko) 2021-04-06
US10577421B2 (en) 2020-03-03
CA3053989A1 (en) 2018-08-30
US11414485B2 (en) 2022-08-16
AU2018226298B2 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
ZA201905790B (en) Anti-lag-3 antibodies and uses thereof
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
PH12018500664B1 (en) Anti-lag3 antibodies and uses thereof
PH12021550764A1 (en) Trem2 stabilizing antibodies
PH12020500078A1 (en) Anti-ctla-4 antibodies and uses thereof
MX2019002867A (es) Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
PH12020550860A1 (en) Anti-trem2 antibodies and related methods
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
MX2021007939A (es) Porciones de union a claudina 18.2 y usos de estas.
NZ774111A (en) Antibodies binding to cd3
PH12018501778A1 (en) Antibodies to tigit
NZ737796A (en) Anti-tau antibodies and methods of use
MX2021014448A (es) Modulacion de celulas mieloides estimulantes y no estimulantes.
MY185845A (en) Icos binding proteins
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
GEAP202014811A (en) Ctla4 binders
JOP20190236A1 (ar) أجسام مضادة لـ ilt4 وشظايا ارتباط بمولد ضد
CN110520441B8 (zh) 抗TGF-β抗体及其用途
PH12016501644B1 (en) Binding proteins and methods of use thereof
MX2018006973A (es) Anticuerpos anti-cd73 humanizados.
MX2019007020A (es) Anticuerpos il-11.
ZA201807920B (en) Anti¿gitr antibodies and uses thereof
EP3964527A3 (en) Combination therapy for cancer
SG10201907161YA (en) Antibodies directed against lymphocyte activation gene 3 (lag-3)
WO2015132675A3 (en) Methods and compositions for modifying the immune response